Indivior Share Discussion Threads

[pngasef] 23/1/2024 17:41

Amazing rebound in the share price, no doubt due to it being vastly oversold.

[casholaa] 19/1/2024 11:38

Shorts

Balyasny Asset Management (Uk) Llp 0.62% 19 Dec 2023
Marshall Wace Llp 0.01% 10 Nov 2021
Marshall Wace Llp 0.50% 2 Nov 2021

[gregmorg] 22/12/2023 09:32

Possibly because the sector is currently out of fashion or out of focus depending on how you see it !

However, the bio and pharma sectors have been like that for a few quarters, very noticeably so in the USA , but it will change -

[casholaa] 20/12/2023 09:05

I occasionally wonder why there is, what seems to me, little appetite for finding a cure for eyes that require spectacles.

[casholaa] 20/12/2023 08:50

Scousers -lol

[adrian j boris] 20/12/2023 08:36

Estimate Cboe Europe 03:32:28 2023-12-20 am EST





1,194.5 GBX +4.14%

[pngasef] 20/12/2023 08:33

How many more things have they got to settle? They seem to have gotten into lots of historic pickles...... almost never ending.

[adrian j boris] 20/12/2023 08:27

Indivior PLC Indivior Settles Patent Dispute with Actavis (3885X)
20/12/2023 7:00am
UK Regulatory (RNS & others)

Indivior (LSE:INDV)




TIDMINDV

RNS Number : 3885X

Indivior PLC

20 December 2023

Indivior Settles Patent Dispute with Teva Subsidiary Actavis

Richmond, VA and Slough UK, December 20, 2023 - Indivior PLC (LSE/NASDAQ: INDV) , a leading addiction treatment company, today announced that its subsidiaries Indivior Inc. and Indivior UK Limited (together, "Indivior") entered into a settlement agreement with Actavis Laboratories UT, Inc. ("Actavis"), a subsidiary of Teva Pharmaceuticals, to resolve patent disputes regarding Actavis's Abbreviated New Drug Application ("ANDA") for generic buprenorphine and naloxone sublingual film. Under the agreement, Indivior granted Actavis a license to U.S. Patent No. 11,135,216 that would enable Actavis to launch the generic film products identified in its ANDA in the United States no earlier than January 31, 2025, unless the unexpired patent claims are found invalid or unenforceable before that time in a final judicial decision.

[waldron] 16/12/2023 10:01

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.

The group's high margin levels account for strong profits.

Thanks to a sound financial situation, the firm has significant leeway for investment.

Over the last twelve months, the sales forecast has been frequently revised upwards.

Analysts covering this company mostly recommend stock overweighting or purchase.

The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

The opinion of analysts covering the stock has improved over the past four months.

There is high visibility into the group's activities for the coming years.

Outlooks on future revenues from analysts covering the equity remain similar.

Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.


Weaknesses

In relation to the value of its tangible assets, the company's valuation appears relatively high.

For the past year, analysts have significantly revised downwards their profit estimates.

For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Over the past twelve months, analysts' opinions have been revised negatively.

The group usually releases earnings worse than estimated.

[waldron] 16/12/2023 09:58

SURPRISED AT CURRENT FREE FALL UNLESS BAD NEWS EXPECTED BY SOME


seems to be over done

[pngasef] 16/12/2023 09:48

Yes!! WTF is going on here?? Bargain of the moment or not? I'm tempted to buy more come Monday.

[dealy] 16/12/2023 08:08

52 week low, despite surging small caps and buy back. very strange

[dealy] 06/12/2023 16:49

It looks like there is overhang here with some institution bailing. Good results and buy back not enough to keep it up

[gregmorg] 06/12/2023 09:57

I must admit the management team looks increasingly unable to get its message across. Very frustrating

[youngers] 05/12/2023 18:29

Five percent down on the court verdict today. Good job they won the case or it could have been really ugly!!

[waldron] 05/12/2023 16:08

Indivior PLC INDV Prevails in Striking Claims in UK Litigation (7595V)
05/12/2023 2:06pm
UK Regulatory (RNS & others)



Tuesday 5 December 2023


TIDMINDV

RNS Number : 7595V


Indivior Prevails in Striking Representative Claims from UK Shareholder Action

Richmond, VA and Slough UK, December 5, 2023 - Indivior PLC (LSE/NASDAQ: INDV) , a leading addiction treatment company, announced that the High Court of Justice of England and Wales has issued a judgment striking out representative claims by Wirral Council as administering authority of Merseyside Pension fund ("Wirral") against Indivior under the Financial Services and Markets Act 2000 ("FSMA"). Wirral's suit was the first attempt by claimants to use representative proceedings for securities claims brought under Sections 90, 90A, and Schedule 10 of the FSMA. The proposed representative proceedings, if allowed, would permit a representative acting on behalf of unnamed claimants to attempt to prove a violation of law without proof of damages, in contrast to ordinary multi-party proceedings, which require proof of liability and damages for each claimant.

In September 2022, Wirral had filed a representative claim generally asserting that Indivior violated the FSMA by making misleading or dishonest statements regarding an alleged fraudulent scheme to switch the market for its SUBOXONE (R) branded products in published information relating to securities. A similar claim was filed against Reckitt Benckiser.

After hearing two days of argument in November 2023, the High Court on December 5 issued a judgment granting Indivior's and Reckitt Benckiser's applications to strike out the representative proceedings. The Court specifically found that it "would be unfair and unjust, and contrary to the overriding objective, to allow the Representative Proceedings to oust the jurisdiction of the Court to case manage the claims from the start." The Court's judgment may be found here .

Wirral and other claimants separately had filed a multi-party action generally alleging the same claims, and levied similar allegations against Reckitt Benckiser Group PLC ("Reckitt Benckiser") in separate actions. Pursuant to the Court's judgment, the claim against Indivior may only proceed in those multi-party proceedings brought by the claimants named in those proceedings.

Wirral may seek permission to appeal the Court's judgment.

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.

Media Contacts :

US Media :

Cassie France-Kelly

Vice President, Communications

Indivior PLC

Tel: [phone]

UK Media :

Teneo

Tel: [phone]

Investors and Analysts :

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: [phone]

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: [phone]

-ends-





(END) Dow Jones Newswires

December 05, 2023 09:06 ET (14:06 GMT)

[waldron] 05/12/2023 16:04

Indivior and Reckitt land legal boost in UK Suboxone claim

Tue, 05th Dec 2023 15:38
Alliance News

(Alliance News) - Indivior PLC and one-time parent Reckitt Benckiser Group PLC were handed a legal victory on Tuesday after the High Court of Justice of England & Wales dismissed a lawsuit related to alleged false marketing of an opioid addiction treatment.

Wirral Council, on behalf of Merseyside Pension fund, looked to bring a representative claim, alleging that Indivior made "misleading or dishonest statements" related to Suboxone-braded products.

"After hearing two days of argument in November 2023, the High Court on December 5 issued a judgment granting Indivior's and Reckitt Benckiser's applications to strike out the representative proceedings," Richmond, Virginia-based pharmaceutical firm Indivior said.

Indivior noted Wirral may seek the green light to appeal the court decision.

Back in October, Indivior said it has reached an agreement to settle a US multi-district Suboxone litigation case, forking out USD385 million in the process.

The litigation was centred on the claim that the pharmaceutical company stymied generic competition for the opioid addiction treatment Suboxone, in order to preserve its dominance.

The settlement marked the end of the multi-district litigation, once approved by the United States District Court for the Eastern District of Pennsylvania.

Indivior was formerly part of Reckitt Benckiser Group PLC, before being spun out in late 2014.

Indivior's share price was down 4.6% at 1,258.00 pence each in London on Tuesday afternoon. Reckitt fell 0.8% to 5,408.00p.

By Hugh Cameron, Alliance News reporter

Comments and questions to [e-mail]

[youngers] 05/12/2023 11:57

The vultures lost for once :)

[gregmorg] 05/12/2023 11:50

I am told that the Wirral class action against R and B and Indivior has been thrown out BUT be careful as I haven't seen anything myself- treat it as heresay till there is some confirmation!

[youngers] 05/12/2023 11:45

So what happened at 11am for that spike?

[steeplejack] 22/11/2023 14:06

Nonetheless,it shows that the company remains vulnerable to litigation from every quarter.

[youngers] 21/11/2023 07:54

I’m thinking this one is covered by DnO insurance?